SCHEMBL19425503

SCHEMBL19425503

COc1ccc(-c2ccc(/C=C3\SC(=S)NC3=O)cn2)cc1OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 7/20 0.69
PDE3A Q14432 6/20 0.69
DYRK1A Q13627 5/20 0.65
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
ALDH1A1 P00352 1/20 0.65
LMNA P02545 1/20 0.65
MAPT P10636 1/20 0.65
NPSR1 Q6W5P4 1/20 0.65
CISD1 Q9NZ45 3/20 0.59
ADAMTS5 Q9UNA0 2/20 0.58
CLK2 P49760 2/20 0.58
CLK1 P49759 1/20 0.58
CLK3 P49761 1/20 0.58
MELK Q14680 1/20 0.58
MAOA P21397 1/20 0.56
MAOB P27338 1/20 0.56
CDC7 O00311 1/20 0.56
PLK4 O00444 1/20 0.56
DAPK3 O43293 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15421279 0.83 PDE4B (1.00) PDE4BPDE3ADYRK1AMEN1KMT2A
SCHEMBL8171885 0.83 PDE4B (1.00) PDE4BPDE3ADYRK1AMEN1KMT2A
SCHEMBL8171882 0.83 PDE4B (1.00) PDE4BPDE3ADYRK1AMEN1KMT2A
SCHEMBL3427116 0.82 MYC (0.51) PDE4BPDE3ADYRK1AMEN1KMT2A
SCHEMBL3427111 0.82 MYC (0.51) PDE4BPDE3ADYRK1AMEN1KMT2A
SCHEMBL3427113 0.82 MYC (0.51) PDE4BPDE3ADYRK1AMEN1KMT2A
SCHEMBL3424781 0.79 PDE4B (0.61) PDE4BPDE3ADYRK1AMEN1KMT2A
SCHEMBL3424778 0.79 PDE4B (0.61) PDE4BPDE3ADYRK1AMEN1KMT2A
SCHEMBL8307071 0.79 PDE4B (1.00) PDE4BPDE3ADYRK1AMEN1KMT2A
SCHEMBL8308532 0.79 PDE4B (1.00) PDE4BPDE3ADYRK1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease UNITY BIOTECHNOLOGY, INC. (US) 2019-02-05 US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 PDE4B 1328/4885PDE3A 3146/4885DYRK1A 4359/4885
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease TP53, CDKN1A, GLA PDE4B 1787/4885PDE3A 3194/4885DYRK1A 3584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.